MTOR and cancer: ,38 To assess whether the PI3K/mTOR pathway controlled immune‐landscape in uLMS could influence immunotherapy response, we evaluated the expression of a pan‐tumour T‐cell inflamed gene signature, which reliably predicts clinical response to PD‐1 blockade in 10 different cancer types, in our cohort of (u)LMS‐TCGA samples.29